The financials
Neurocrine Biosciences, Inc. by the numbers
Neurocrine Biosciences, Inc. (NBIX) reported revenue of $815M in Q1 2026 (quarter ended March 31, 2026), up 42% from the same quarter a year earlier. That came with a gross margin of 98% and net income of $198M (24% of revenue). For the full year FY2025, revenue was $2.86B (+21% year on year) and net income $479M. Its largest product in 2025-Q1 was Collaboration at $8.9M, 57% of the disclosed total, just ahead of Royalty at 43%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $815M | $573M | +42% |
| Gross profit | $801M | $563M | +42% |
| Operating income | $193M | $24M | +719% |
| Net income | $198M | $7.9M | +2405% |
| Diluted EPS | $1.91 | $0.08 | +2288% |
| Product | Revenue | Share |
|---|---|---|
| Collaboration | $8.9M | 57% |
| Royalty | $6.7M | 43% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $4.7M (+34%)
Collaboration grew -15% year on year
Segment Latestquarter on quarteryear on year
- Collaboration$4.7M$4.7MQoQ +34%year on year -15%+34%-15%
Drug Manufacturers - Specialty & Generic
Ranks #8 of 28 by Smart Score